Horizon Pharma (HZNP -1.8%) receives a marketing authorization from the UK Medicines and...

|About: Horizon Pharma plc (HZNP)|By:, SA News Editor

Horizon Pharma (HZNP -1.8%) receives a marketing authorization from the UK Medicines and Healthcare products Regulatory Agency for Duexis, for the treatment of osteoarthritis, rheumatoid arthritis and ankylosing spondylitis and to decrease the risk of developing upper gastrointestinal ulcers. The authorization stemmed from the favorable recommendation coming out of the Commission on Human Medicines.